Tech refresher: Helping patients get a grip on arthritis First IL-6 receptor inhibitor for rheumatoid arthritisHoffmann-La Roche will soon be introducing Actemra (tocilizumab), the first interleukin-6 (IL-6) receptor inhibitor to be approved for the treatment of rheumatoid arthritis (RA). Popular assessment tool a poor predictor of cardiovascular risk in rheumatoid arthritis patients Rheumatoid arthritis care remains suboptimal Canadian study suggests early, aggressive treatment has not caught on in primary care, especially DMARDs Possible link found between rheumatoid arthritis biologics and certain skin cancers Overall risk remains low, but increased incidences seen with anti-tumour necrosis factor drugs Novel drug shows promise in rheumatoid arthritis Predictors of hip disease risk found in juvenile arthritis CE Lesson: Update On Rheumatoid Arthritis Gene therapy not to blame in woman's death New biologic approved for RA, psoriatic arthritis and ankylosing spondylitis Schering-Plough has received Health Canada approval to market Simponi (golimumab) subcutaneous injection. First Previous 19 20 21 Next Last
